Dimethaid Research Inc. is a fully integrated pharmaceutical company headquartered in Canada with subsidiaries in Europe, Asia and the Caribbean.
The company is focused on the commercialization of therapeutics designed to produce minimal side effects.
Dimethaid is engaged in all stages of pharmaceutical development, from R&D, through clinical and regulatory filing, to full-scale manufacturing and marketing.
Dimethaid Research Inc. trades on the Toronto Stock Exchange under the symbol DMX.
